Overview

Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment

Status:
Completed
Trial end date:
2016-01-11
Target enrollment:
Participant gender:
Summary
Evaluate the proportion of patients with an urticaria control test [UCT] score of greater than or equal to 12 at Week 12.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Histamine Antagonists
Histamine H1 Antagonists
Omalizumab